Open AccessSeven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer
Author(s) -
S.M. Tolaney,
H. Guo,
S. Pernas,
W.T. Barry,
D.A. Dillon,
L. Ritterhouse,
B.P. Schneider,
Fengfang Shen,
K. Fuhrman,
M. Baltay,
C.T. Dang,
D.A. Yardley,
B. Moy,
P.K. Marcom,
K.S. Albain,
H.S. Rugo,
M.J. Ellis,
I. Shapira,
A.C. Wolff,
LA Carey,
B. Overmoyer,
A.H. Partridge,
C.A. Hudis,
I.E. Krop,
H.J. Burstein,
E.P. Winer
Publication year - 2019
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/8hhr-k187
Subject(s) - trastuzumab , human epidermal growth factor receptor 2 , paclitaxel , breast cancer , oncology , adjuvant , medicine , epidermal growth factor receptor , cancer research , cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom